Insmed Inc - Company Profile
Powered by 
All the sales intelligence you need on Insmed Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Insmed Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Insmed Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Insmed Inc (Insmed) is a biopharmaceutical company that focuses on developing novel therapeutics for rare diseases. Its marketed product, Arikayce (liposomal amikacin for inhalation) an inhalation suspension used for the treatment of nontuberculous mycobacterial lung infections. The company uses its proprietary liposomal technology to develop its novel drug candidates. Its pipeline products include brensocatib for non-cystic fibrosis (non-CF) bronchiectasis; TPIP, an inhaled formulation of a treprostinil prodrug for pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis, and PAH associated with interstitial lung diseases. The company operates in the US, the UK, the Netherlands, Ireland, Germany, Italy, France, and Japan through its subsidiaries. Insmed is headquartered in Bridgewater, New Jersey, the US
Headquarters
United States of America
Address
700 Us Highway 202/206, Bridgewater, New Jersey, 08807
Website
www.insmed.com
Telephone
1 908 9779900
No of Employees
1,664
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
INSM (NASD)
Revenue (2024)
$606.4M
66.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-39.7%
(2024 vs 2023)
Market Cap*
$23.2B
Net Profit Margin (2024)
XYZ
16.2%
(2024 vs 2023)
* As of and is in US$
Insmed Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Amikacin Liposome Inhalation Suspension | Arikayce |
| Pipeline | Brensocatib |
| Brensocatib: Non-Cystic Fibrosis Bronchiectasis (NCFB) | Insmed |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Others | In December, the company acquired INS1148, a Phase 2-ready monoclonal antibody from Opsidio. |
| 2025 | Regulatory Approval | In November, the company secured approval from the European Commission BRINSUPRI (brensocatib 25 mg tablets) to treat patients with non-cystic fibrosis bronchiectasis in patients 12 years of age and older with two or more exacerbations in the prior 12 months. |
| 2025 | Regulatory Approval | In February, the company received New Drug Application (NDA) approval from the U.S. Food and Drug Administration (FDA) for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. |
Competitor Comparison
| Key Parameters | Insmed Inc | Teva Pharmaceutical Industries Ltd | Vertex Pharmaceuticals Inc | Paratek Pharmaceuticals Inc | Spero Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Israel | United States of America | United States of America | United States of America |
| City | Bridgewater | Tel Aviv | Boston | Boston | Cambridge |
| State/Province | New Jersey | Tel Aviv | Massachusetts | Massachusetts | Massachusetts |
| No. of Employees | 1,664 | 31,173 | 6,400 | 269 | 25 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William H. Lewis | Chairman; Chief Executive Officer | Executive Board | 2012 | 57 |
| Sara M. Bonstein | Chief Financial Officer | Senior Management | 2020 | 45 |
| Roger Adsett | Chief Operating Officer | Senior Management | 2019 | 57 |
| Michael A. Smith | Chief Legal Officer | Senior Management | 2014 | 49 |
| Martina Flammer, MD | Chief Medical Officer | Senior Management | 2019 | 62 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer